bymuratdeniz Parabilis Medicines ( PBLS ) priced its upsized IPO of 33.3M shares at $19 per share, the top end of its marketed range, raising approximately $633.3M in gross proceeds. The underwriters have a 30-day option to buy an additional ~5M shares . The common stock is expected to begin trading on the Nasdaq on June 10, 2026 under the ticker symbol “PBLS”. The offering is expected to close on...
bymuratdeniz Parabilis Medicines ( PBLS ) priced its upsized IPO of 33.3M shares at $19 per share, the top end of its marketed range, raising approximately $633.3M in gross proceeds. The underwriters have a 30-day option to buy an additional ~5M shares . The common stock is expected to begin trading on the Nasdaq on June 10, 2026 under the ticker symbol “PBLS”. The offering is expected to close on or about June 11, 2026. Alongside the shares offered in the IPO, Parabilis agreed to sell 4.17 million shares of common stock to Regeneron Pharmaceuticals ( REGN ) in a concurrent private placement at $18.00 per share, representing a 10% discount to the IPO price of $19.00 per share. Parabilis expects to raise ~$670M in gross proceeds from its IPO, and $75M from the concurrent private placement with Regeneron ( REGN ) More on Parabilis Medicines, Inc. Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials Parabilis upsizes IPO seeking to raise more than $600M Regeneron backed Parabilis seeks up to $476M in U.S. IPO Financial information for Parabilis Medicines, Inc.
bymuratdeniz Parabilis Medicines ( PBLS ) priced its upsized IPO of 33.3M shares at $20 per share. The underwriters have a 30-day option to buy an additional ~5M shares . The common stock is expected to begin trading on the Nasdaq on June 10, 2026 under the ticker symbol “PBLS”. The offering is expected to close on or about June 11, 2026. Alongside the shares offered in the IPO, Parabilis agreed t...
bymuratdeniz Parabilis Medicines ( PBLS ) priced its upsized IPO of 33.3M shares at $20 per share. The underwriters have a 30-day option to buy an additional ~5M shares . The common stock is expected to begin trading on the Nasdaq on June 10, 2026 under the ticker symbol “PBLS”. The offering is expected to close on or about June 11, 2026. Alongside the shares offered in the IPO, Parabilis agreed to sell 4.17 million shares of common stock to Regeneron Pharmaceuticals ( REGN ) in a concurrent private placement at $18 per share, representing a 10% discount to the IPO price of $20.00 per share. Parabilis expects to raise ~$670M in gross proceeds from its IPO, and $75M from the concurrent private placement with Regeneron ( REGN ) More on Parabilis Medicines, Inc. Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials Parabilis upsizes IPO seeking to raise more than $600M Regeneron backed Parabilis seeks up to $476M in U.S. IPO Financial information for Parabilis Medicines, Inc.
(RTTNews) - Starbucks Corp. (SBUX) is exploring strategic options for its Japan business, including a potential stake sale, Bloomberg reported Wednesday citing people familiar with the matter.
(RTTNews) - Starbucks Corp. (SBUX) is exploring strategic options for its Japan business, including a potential stake sale, Bloomberg reported Wednesday citing people familiar with the matter.